IfPA Offers the Physician’s Perspective on Oncology Value Models
What is good value in terms of cancer treatment? The question, amid rising cancer care costs, has prompted a surge of oncology value models in recent years.
Are New Cancer Meds Worth Their Cost?
Innovative but costly anti-cancer drugs have spurred the development of several value assessments and cost frameworks, all designed to explore one question: Do the benefits of these treatments justify their price? Now, new research published in Health Affairs suggests that these treatments may significantly extend the life expectancy of some cancer patients.
